Randomized, Double-blind Trial
N = 18,201

Patient Population

  • Aged ≥18 years
  • Patients with NVAF or atrial flutter and 1 or more risk factors for stroke
double arrow

Apixaban 5 mg BID, oral
(2.5 mg BID, oral in select patients)

Warfarin
(Adjusted to an INR of 2-3)

Primary Efficacy Outcome

  • Stroke and SE

Primary Safety Outcome

  • Major bleeding§

Key Secondary Outcome

  • All-cause death

Median duration of exposure was
1.7 years

1034 centers
39 countries